Aspire Biopharma's Buzz Bomb Caffeine Company Partners with Interwest Brokerage to Accelerate Retail Expansion
Rhea-AI Summary
Aspire Biopharma (Nasdaq:ASBP) subsidiary Buzz Bomb Caffeine Company has signed a sales and marketing brokerage agreement with Interwest Brokerage to expand BUZZ BOMB™ retail distribution across Utah, Idaho, and Montana.
The partnership assigns Interwest to lead sales, marketing, and distribution in grocery, convenience, and alternate channels to increase shelf presence and product velocity.
Positive
- None.
Negative
- None.
News Market Reaction – ASBP
In the Apr 15 session, ASBP declined 54.21%, reflecting a significant negative market reaction. Argus tracked a peak move of +7.8% during that session. Argus tracked a trough of -82.3% from its starting point during tracking. Our momentum scanner triggered 62 alerts that day, indicating high trading interest and price volatility. Trading volume was exceptionally heavy at 14.0x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Partnership Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Mar 03 | Drug development partnership | Positive | +1.4% | Partnership to develop rapid-delivery sublingual alprazolam powder formulation. |
| Feb 03 | Distribution partnership | Positive | -4.1% | Buzz Bomb partners with Blue Shark to expand Southern California distribution. |
| Nov 06 | Partnership outreach | Positive | -23.9% | Engagements with global pharma at CPHI Frankfurt on aspirin program partnerships. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Partnership headlines have often been followed by negative price moves, with an average move of -8.87%, indicating a pattern of skepticism toward such announcements.
Recent partnership news for Aspire Biopharma has spanned both its pharmaceutical pipeline and its Buzz Bomb consumer product. On Nov 6, 2025, partnership outreach around sublingual high-dose aspirin was followed by a steep negative move. In Feb 2026, a Buzz Bomb distribution partnership in Southern California also saw a post-news decline. A Mar 3, 2026 alprazolam powder partnership produced a modest gain, making today’s Buzz Bomb brokerage deal another step in a multi-pronged partnering strategy.
Key Terms
consumer packaged goods (cpg) technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
Interwest to Drive Regional Growth for BUZZ BOMB™ Across Major Grocery and Convenience Channels
ESTERO, FL / ACCESS Newswire / April 15, 2026 / Aspire Biopharma Holdings, Inc.'s (Nasdaq:ASBP) ("Aspire" or the "Company") wholly owned subsidiary, Buzz Bomb Caffeine Company, today announced a strategic sales and marketing brokerage agreement with Interwest Brokerage ("Interwest"). This partnership is designed to scale BUZZ BOMB™'s retail footprint across the grocery, convenience, and alternate channel sectors throughout the Intermountain West.
Headquartered in Salt Lake City, Interwest is a premier independent Consumer Packaged Goods (CPG) solutions provider known for its high-impact retail execution. Under the new agreement, Interwest will spearhead the sales, marketing, and distribution strategy for BUZZ BOMB™ across Utah, Idaho, and Montana. The partnership leverages Interwest's deep-rooted relationships with powerhouse regional and national retailers.
"Interwest represents the gold standard for brokerage in the grocery and convenience sectors," said Kraig Higginson, Interim CEO of Aspire Biopharma. "Their track record of executing dynamic sales strategies and precision marketing makes them the ideal partner as we enter this next phase of aggressive retail expansion. By aligning with Interwest, we are positioning BUZZ BOMB™ to capture market share in a key region for the functional beverage and energy categories."
By integrating Interwest's comprehensive support services and localized market expertise, BUZZ BOMB™ aims to rapidly increase product velocity and shelf presence. This collaboration marks a significant milestone in Aspire's broader mission to bring its innovative caffeine delivery systems to a national consumer base.
BUZZ BOMB™ Caffeine Products
Unlike traditional energy drinks or pills, BUZZ BOMB™ is a new and exciting caffeine product delivered in a single-serving stick pack of dry powder sprinkled under the tongue. This method provides flavored caffeine quickly without the hassle of mixing with water or consuming typical caffeine sources like energy drinks, coffee, or soda.
BUZZ BOMB™ features 50mg of caffeine and is currently offered in four delicious flavors: Tropical Fruit, Mixed Berry, Peach Mango, and Coffee Mocha. Designed for athletes, professionals, and the everyday person needing a rapid boost, BUZZ BOMB™ provides a precise serving of caffeine and flavor in easy-to-use single serving stick packs.
To learn more about BUZZ BOMB™, or purchase product online, please visit https://buzzbombcaffeine.com or follows us on social media here:
BUZZ BOMB™ Variety Pack
About Interwest Brokerage
Since its founding in 1978, Interwest Brokerage has been the leading independent CPG sales and marketing solution in Idaho, Montana, Utah, and Wyoming. Headquartered in Salt Lake City, serving manufacturers of confection, food, non-food, and general merchandise in the grocery, convenience and alternate channel areas.
For more information, please visit: https://www.interwestbrokerage.com/
About Aspire Biopharma Holdings, Inc.
Aspire Biopharma delivers supplements to the body rapidly and precisely.
For more information, please visit www.aspirebiolabs.com
Aspire Biopharma Holdings, Inc.
Contact
PCG Advisory
Kevin McGrath
+1-646-418-7002
kevin@pcgadvisory.com
Safe Harbor Statement
This press release contains "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the "safe harbor" provisions created by those laws. Aspire's forward-looking statements include, but are not limited to, statements regarding our or our management team's expectations, hopes, beliefs, intentions or strategies regarding our future operations. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words "anticipate," "believe," "contemplate," "continue," "estimate," "expect," "intends," "may," "might," "plan," "possible," "potential," "predict," "project," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements represent our views as of the date of this press release and involve a number of judgments, risks and uncertainties. We anticipate that subsequent events and developments will cause our views to change. We undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date. As a result of a number of known and unknown risks and uncertainties, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements. Some factors that could cause actual results to differ in our drug or supplement offerings include general market conditions, whether clinical trials demonstrate the efficacy and safety of our drug candidates to the satisfaction of regulatory authorities, or do not otherwise produce positive results which may cause us to incur additional costs or experience delays in completing, or ultimately be unable to complete the development and commercialization of our drug candidates; the clinical results for our drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; our ability to achieve commercial success for our drug or supplement candidates, if approved; our limited operating history and our ability to obtain additional funding for operations and to complete the development and commercialization of our product candidates, and other risks and uncertainties set forth in "Risk Factors" in our most recent Annual Report on Form 10-K and any subsequent Quarterly Reports on Form 10-Q. In addition, statements that "we believe" and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this press release, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to rely unduly upon these statements. All information in this press release is as of the date of this press release. The information contained in any website referenced herein is not, and shall not be deemed to be, part of or incorporated into this press release.
SOURCE: Aspire Biopharma Holdings, Inc.
View the original press release on ACCESS Newswire